{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:06Z","timestamp":1772166426796,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Science and Technology Major Project of China during the 13th Five-Year Plan Period","award":["2018ZX10302104001"],"award-info":[{"award-number":["2018ZX10302104001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus retinitis (CMVR) is an important opportunistic infection (OI) occurring mainly in patients with acquired immunodeficiency syndrome (AIDS) and has the potential to cause severe visual impairment and blindness among AIDS patients. Subsequent to the adoption and implementation of widespread antiretroviral therapy (ART), the prognosis of AIDS-associated CMVR has been substantially improved. Nevertheless, the equivocal clinical evidence as regards the optimal timing for ART initiation in patients with an established CMVR diagnosis is required. We therefore designed the present study in order to investigate the optimal timing for ART initiation in AIDS\/CMVR patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This will be a prospective, randomized controlled trial to be performed at 17 hospitals in mainland China. A total of 300 participants with CMVR will be randomly assigned to an early ART initiation group (ART initiation within 2\u2009weeks after anti-CMV therapy), or a deferred ART initiation group (initiation of ART more than 2\u2009weeks after anti-CMV therapy) at a 1:1 ratio. All participants will receive 48\u00a0weeks of follow-up after anti-CMV therapy initiation. Our primary outcome will be the incidence of visual loss (to a visual acuity worse than 20\/40 or 20\/200) in the two groups during the 48-week follow-up period. Secondary outcomes will include changes in HIV virological suppression and serum CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell counts, the incidence of mortality, retinitis progression (movement of the peripheral border of a CMV lesion \u2265 \u00bd disc diameter, or occurrence of a new CMV lesion), retinal detachment, immune recovery uveitis (IRU), and other OIs and adverse events between the two study groups during the 48\u2009weeks of follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The study aims to investigate the optimal timing for ART initiation in AIDS\/CMVR patients. We hope to be able to extract robust clinical evidence for use in optimal AIDS\/CMVR management should our trial be successful.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      This research was registered as one of the twelve clinical trials under the name of a general project \u201cA study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections\u201d, ChiCTR1900021195. Registered on 1 February 2019,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=35362\">http:\/\/www.chictr.org.cn\/showproj.aspx?proj=35362<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-021-05159-y","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:13:08Z","timestamp":1616080388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Timing of antiretroviral therapy for HIV-infected patients with cytomegalovirus retinitis: study protocol of a multi-center prospective randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiao-Qing","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Qiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Yuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Quan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Harypursat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Qiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"5159_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0002-9394(01)01322-8","volume":"133","author":"DA Jabs","year":"2002","unstructured":"Jabs DA, Van Natta ML, Kempen JH, Pavan PR, Lim JI, Murphy RL, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2002;133:48\u201361.","journal-title":"Am J Ophthalmol"},{"key":"5159_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7326\/0003-4819-125-7-199610010-00008","volume":"125","author":"JR Arribas","year":"1996","unstructured":"Arribas JR, Storch GA, Clifford DB, Tselis AC. Cytomegalovirus encephalitis. Ann Intern Med. 1996;125:577\u201387.","journal-title":"Ann Intern Med"},{"key":"5159_CR3","first-page":"S29","volume":"4","author":"DT Dieterich","year":"1991","unstructured":"Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr. 1991;4:S29\u201335.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"5159_CR4","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1093\/infdis\/jiw217","volume":"214","author":"S Gianella","year":"2016","unstructured":"Gianella S, Letendre S. Cytomegalovirus and HIV: a dangerous pas de Deux. J Infect Dis. 2016;214(Suppl 2):S67\u201374.","journal-title":"J Infect Dis"},{"key":"5159_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ophtha.2006.08.008","volume":"114","author":"JE Thorne","year":"2007","unstructured":"Thorne JE, Holbrook JT, Jabs DA, Kempen JH, Nichols C, Meinert CL, et al. Effect of cytomegalovirus retinitis on the risk of visual acuity loss among patients with AIDS. Ophthalmology. 2007;114:591\u20138.","journal-title":"Ophthalmology"},{"key":"5159_CR6","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.ajo.2011.11.014","volume":"153","author":"EA Sugar","year":"2012","unstructured":"Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP, Meinert CL, et al. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol. 2012;153:1016\u201324 e5.","journal-title":"Am J Ophthalmol"},{"key":"5159_CR7","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.ophtha.2015.02.033","volume":"122","author":"DA Jabs","year":"2015","unstructured":"Jabs DA, Ahuja A, Van Natta ML, Lyon AT, Yeh S, Danis R, et al. Long-term outcomes of cytomegalovirus retinitis in the era of modern antiretroviral therapy: results from a United States cohort. Ophthalmology. 2015;122:1452\u201363.","journal-title":"Ophthalmology"},{"key":"5159_CR8","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/cid\/ciu648","volume":"59","author":"N Tun","year":"2014","unstructured":"Tun N, Smithuis FM, London N, Drew WL, Heiden D. Mortality in patients with AIDS-related cytomegalovirus retinitis in Myanmar. Clin Infect Dis. 2014;59:1650\u20131.","journal-title":"Clin Infect Dis"},{"key":"5159_CR9","first-page":"65","volume":"4","author":"Hepatitis C Scientific Group","year":"2019","unstructured":"Hepatitis C Scientific Group, Chinese Association of Infectious Diseases. Guidelines for the Diagnosis and Treatment of AIDS in China (2018 edition). Electron J Emerg Infect Dis. 2019;4:65\u201384.","journal-title":"Electron J Emerg Infect Dis"},{"key":"5159_CR10","unstructured":"Adolescents PoOIiH-IA. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2019."},{"key":"5159_CR11","first-page":"2152-61.e1","volume":"117","author":"DA Jabs","year":"2010","unstructured":"Jabs DA, Ahuja A, Van Natta M, Lyon A, Srivastava S, Gangaputra S, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes. Ophthalmology. 2010;117:2152-61.e1\u20132.","journal-title":"Ophthalmology"},{"key":"5159_CR12","doi-asserted-by":"publisher","first-page":"971417","DOI":"10.1155\/2014\/971417","volume":"2014","author":"B Urban","year":"2014","unstructured":"Urban B, Bakunowicz-Lazarczyk A, Michalczuk M. Immune recovery uveitis: pathogenesis, clinical symptoms, and treatment. Mediat Inflamm. 2014;2014:971417.","journal-title":"Mediat Inflamm"},{"key":"5159_CR13","volume-title":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1","author":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS","year":"2017","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. 2017. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf. Accessed 17 May 2020."},{"key":"5159_CR14","volume-title":"What is a Serious Adverse Event?","author":"U.S. Food and Drug Administration","year":"2016","unstructured":"U.S. Food and Drug Administration. What is a Serious Adverse Event? 2016. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Accessed 17 May 2020."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05159-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-021-05159-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05159-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T15:22:25Z","timestamp":1616080945000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05159-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5159"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05159-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-33101\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"15 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of Chongqing Public Health Medical Center (2019-003-02-KY) and has been registered as one of the twelve trials under a general project at clinicaltrials.gov. The registration number of the general project is ChiCTR1900021195. The approval of the Ethics Committees from each participating site will be secured before initiation of patient recruitment.Our research results will be shared through published medical journal articles and conference presentations after completion of the study.Written informed consent will be obtained from each participants before randomization by attending doctors. All participants will sign informed consent before enrolment in the study. All informed consent will be stick on CRFs by investigator.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}